Del Federal Judge Tosses Medical Cream Maker s FCA Suit law360.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from law360.com Daily Mail and Mail on Sunday newspapers.
/US Irritable Bowel Syndrome Treatment Market Revenue to Cross US$ 1,276.21 Mn in 2027 | Market Seeks to New Posture of Market Trends, Opportunities and Breakthrough Point During 2021-2027
US Irritable Bowel Syndrome Treatment Market Revenue to Cross US$ 1,276.21 Mn in 2027 | Market Seeks to New Posture of Market Trends, Opportunities and Breakthrough Point During 2021-2027
The US irritable bowel syndrome treatment market is expected to reach US$ 1,276.21 Mn in 2027 from US$ 586.61 Mn in 2019. The market is estimated to grow with a CAGR of 10.3% from 2020-2027.
tipApril 12, 2021
Worldwide
US Irritable Bowel Syndrome Treatment Market Analysis to 2027 is a specialized and in-depth study of the
Irritable Bowel Syndrome Treatment Market to reach US$ 1,276 21 Mn in 2027 to grow with a CAGR of 10 3% - Lannett Company, Sebela Pharmaceuticals, Synthetic Biologics texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Pharmaceutical Cos. Accuse Competitor of Falsely Advertising Cream as FDA-Approved Generic
December 11, 2020
Sebela Pharmaceuticals Inc. and Perrigo New York, Inc. have filed a complaint against TruPharma, LLC for supposedly deceiving members of the public and the pharmaceutical industry that a topical cream it sells is generically equivalent to Sebela’s branded cream and Perrigo’s authorized version. Thursday’s District of Delaware complaint centers on Sebela’s trademarked Pramosone product, a corticosteroid available only by prescription.
According to the filing, Sebela markets, distributes, and sells pharmaceuticals in the gastroenterology and dermatology fields; the aforementioned cortisone cream and a similar one, both sold by Sebela, have been on the market for over 30 years. Sebela contends that it has dedicated significant resources to building its reputation and creating goodwill in connection with Pramosone.